Abstract
Liquid biopsy, a non-invasive method for analyzing circulating biomarkers in bodily fluids, has garnered significant interest as a potential alternative to traditional surgical tissue biopsy in oncology. This review explores the current landscape of liquid biopsy technologies, their clinical applications, and their potential to complement or replace surgical tissue biopsy in cancer diagnosis, treatment monitoring, and prognostication. We examine the various analytes detected in liquid biopsies, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and microRNAs, and discuss their utility in detecting genetic alterations, assessing treatment response, and monitoring disease progression. Furthermore, we compare the advantages and limitations of liquid biopsy with surgical tissue biopsy, highlighting factors such as invasiveness, accessibility, and the ability to capture tumor heterogeneity. We also address ongoing challenges in standardization, sensitivity, and specificity of liquid biopsy assays and discuss future directions aimed at optimizing their clinical utility. Overall, this review provides insights into the evolving role of liquid biopsy as a potential alternative to surgical tissue biopsy in oncology and underscores its potential to improve patient care and outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal For Multidisciplinary Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
